Promising results for MF Trial - Pacritinib

[Paul123456]

jamanetwork.com/journals/ja...

A trial comparing pacritinib daily dose of 400mg versus pacritinib daily 2 x 200mg versus Best Available Therapy (BAT).

BAT was primarily Ruxo/Jakafi.

Perhaps the most interesting bit is the number of participants who switched mid trial from BAT to Pacritinib after 24 weeks!

“Conclusions and Relevance:

In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.”

Hopefully we will soon hear a lot more about Pacritinib and in language more easily assimilated by us laypersons.

[Paul123456]

Here is a video explaining benefits of Pacritinib over Ruxo, especially for MF patients with low Platelets

targetedonc.com/conference/...

However this is dated 2017 and the link above 8th March 2018

I know Pacritinib was suspended (safely concerns) and then re-approved early 2017 but not sure how these two trials connect, sound similar in principle. I assume same trial but 2018 is latest update?